Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8055 · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| AZD8055 | EXPERIMENTAL | Dose escalation |
| 1 | EXPERIMENTAL | The study will start with AZD8055 formulated in a liquid solution prior to the tablet formulation becoming available. The tablet formulation will be introduced in Part A at the beginning of a new cohort at an appropriate dose, no higher than the dose of the liquid formulation in the last completed evaluated cohort. Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment. |
| Name | Type | Description |
|---|---|---|
| AZD8055 | DRUG | Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal. |
Inclusion Criteria: * Advanced stage Hepatocellular Carcinoma (HCC) confirmed by cytology or histology * Advanced stage Hepatocellular Carcinoma (HCC) or metastatic Hepatocellular Carcinoma (HCC) which is inoperable and incurable with standard available treatments * Relatively good overall health o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AZD8055 is an investigational small molecule being studied for the treatment of cancer, including solid tumors and advanced hepatocellular carcinoma. It is a TOR kinase inhibitor developed by AstraZeneca PLC. As of now, it has been evaluated in early-phase clinical trials, but it is not approved for any indication.
AZD8055 targets TOR kinase, a key regulator of cell growth and proliferation. By inhibiting this enzyme, the drug aims to disrupt signaling pathways that drive tumor growth. This mechanism is being explored in the context of advanced solid malignancies and liver cancer, though the drug remains in clinical development.
AZD8055 is developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. The company has sponsored clinical trials to evaluate the safety and efficacy of this investigational drug in patients with various types of cancer.
AZD8055 is in Phase 1 clinical development. All three trials listed for this drug are Phase 1 studies, and they have been completed. The drug is still investigational and has not received regulatory approval for any use. Its development status reflects early-stage evaluation of safety and tolerability.
AZD8055 has been studied in three completed Phase 1 trials: NCT00731263 in advanced tumors, NCT00973076 in cancer and solid tumors, and NCT00999882 in advanced hepatocellular carcinoma. These trials enrolled a total of 109 patients across the United States, France, the United Kingdom, Japan, Hong Kong, and South Korea.
AZD8055 is a TOR kinase inhibitor, meaning it works by blocking the activity of TOR kinase enzymes. It is not known by any other drug name, but it is often described by its mechanism of action. The drug is being investigated for its potential role in treating cancer, though it remains in early clinical testing.